COL4A6 is highly downregulated in prostate cancer, and its deletion can promote prostate cancer progression and metastasis by activating the p-focal adhesion kinase (FAK)/matrix metallopeptidase 9 (MMP-9) signaling pathway (17). Here, PTK2 is linked to prostate carcinoma.